Publications & News

12/19/22 Madrigal announces positive topline results for phase 3 resmetirom study. Gfree Bio contributed to the resmetirom program and if it comes to market it will be the first therapeutic for NASH (Nonalcohol steatohepatitis disease).

11/16/22 Publication with Nura Bio on neuroprotective adduct-forming SARM1 inhibitors

8/1/22 Publication with NodThera Ltd Discovery and optimization of triazolopyrimidinone derivatives as selective NLRP3 inflamasome inhibitors

2/1/22 Gilead and ViiV announce $1.25 billion settlement of their patent litigation over biktarvy and dolutegravir. Gfree Bio provided critical expert testimony on behalf of Gilead.

1/2/21 Kate Holloway, Principal Scientist at Gfree Bio, is awarded the ACS computers in chemistry and pharmaceutical research award

4/13/20 Compounds that interact with the RAS superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease. United States Patent, US11,026,930

9/17/18 Registration is open for the 4th Drug Discovery Re-Invented conference scheduled to take place starting February 21, 2019. Fusion Conferences

6/28/18 Gfree Bio presented at the Chemical Computing Group North American UGM

5/15/18 Method of synthesizing thyroid hormone analogs and polymorphs thereof. United States Patent, US 9,968,612 (Resmetirom). C. Reynolds of Gfree Bio is a coinventor.

2/12/18 See highlighted papers in the recent issue of ACS Medicinal Chemistry Letters

1/2/18 Gfree Bio recently published an article titled Group Additivity in Ligand Binding Affinity: An Alternative Approach to Ligand Efficiency

8/20/17 Kate Holloway received a Heroes of Chemistry award from the American Chemical Society to recognize the Merck team who invented ZEPATIER®, a significant new treatment for chronic Hepatitis C Virus infection. To see a short video about this discovery, click here. For more information on the Heroes of Chemistry award, click here.

1/2/17 Gfree Bio is happy to welcome Dr. M. Katharine Holloway. Kate brings significant expertise and experience in structure-based drug design after a highly successful career at Merck that included the invention of marketed protease inhibitors to treat HIV (Crixivan™) and HCV (Vanihep™ and Zepatier™). For more info, check out her bio.

7/11/16 Gfree Bio has been awarded an NIH Phase I STTR grant from NIGMS for a program titled: Polar samplng and optimization of protein-ligand cocrystal structures. Dr. Charles H. Reynolds, Founder of Gfree Bio, is Principal Investigator.

5/21/16 Gfree Bio to present at the CCG UGM in June.

4/1/16 Gfree Bio collaborator Nirvana Sciences has been awarded Phase II NIH SBIR grant.

3/14/16 Gfree Bio founder presented at the ACS National meeting in San Diegothemputers in Chemistry MPPG session.

11/25/15 Gfree Bio collaborator OptiKira awarded two NIH Grants.

9/23/15 The third Drug Discovery Reinvented Conference has been announced for February 21, 2017 in Cancun, Mexico.

8/17/15 Ligand efficiency metrics: Why all the fuss?

5/13/15 Gfree Bio was recently profiled by the Kauffman Foundation.

5/13/15 The second Drug Discovery Reinvented Conference is scheduled for August of 2015. See the outstanding lineup of speakers.

5/1/15 European patent published for collaborative work with Madrigal Pharmaceuticals. D. Keith Hester, Robert J. Duguid, Martha Kelly, Anna Chasnoff, Gang Dong, Edwin L. Crow, Rebecca Taub, Charles H. Reynolds, Duk Soon Choi, Lianhe Shu, Ping Wang Method of synthesizing thyroid hormone analogs and polymorphs thereof, Madrigal Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., PCT/US2013/060177, Mar 20, 2014.

2/25/15 Gfree Bio is collaborating with OptiKira to develop new therapeutics to prevent cell death. OptiKira is a BioMotiv company.

2/10/15 The Vibrant Philly Biotech Scene: Focus on Computer-aided Drug Design and Gfree Bio, LLC.

1/26/15 NIH Phase II SBIR awarded to Phelix Therapeutics for development of pan-coronavirus inhibitors. Gfree Bio is collaborating with Phelix on this program.

6/15/14 NIH Phase II SBIR awarded to Vironika, LLC. Gfree Bio is a collaborator for this SBIR award.

Two recent publications from Gfree Bio among most read in ACS Med. Chem. Letters. These are: Protein-Ligand Cocrystal structures: We Can Do Better and Validity of Ligand Efficiency Metrics

5/1/2014 NIH Phase I STTR awarded to PPI Mimics. Charles H. Reynolds, Principal Investigator.

1/31/14 The role of ligand efficiency metrics in drug discovery

7/16/13 NIH STTR awarded FCCDC and Drexel College of Medicine. Collaboration with Gfree Bio.

Selected Publications by Charles H. Reynolds:

Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Thermodynamics of ligand binding and efficiency

Drug Design: Structure and Ligand Based Approaches

Contact Us

Request Information

Thank you for your interest in Gfree Bio, LLC. To learn more simply fill out our contact form. Thank you.

Contact Information

      Full Name*